Rapid Evolution of the KRAS Inhibitors Market: A Projected 36% CAGR by 2032, According to DelveInsight Analysis | Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines, Roche, Genentech

DelveInsight's "KRAS Inhibitors Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the KRAS Inhibitors, historical and forecasted epidemiology as well as the KRAS Inhibitors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the KRAS Inhibitors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; KRAS Inhibitors Market Forecast
https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the KRAS Inhibitors Market Report:
• The KRAS Inhibitors market size was valued approximately USD 240 million in 2022 and is anticipated to grow with a significant CAGR of 36% during the study period (2019-2032)
• In 2022, there were more over 490,000 KRAS-mutated cases in the 7MM, and this number is expected to rise over the predicted period
• The majority of KRAS mutant instances among the chosen cancer types are found in colorectal cancer, followed by pancreatic cancer and NSCLC. About 205,889 instances of KRAS mutant colon cancer were reported in the 7MM in 2019
• Nearly half of KRAS-mutant patients exhibited TP53 mutations, followed by STK11 (18% to 28%) and KEAP1 (24%) in the Pons-Tostivint et al. 2021 study
• In 119 KRAS mutated patients, 69 patients were found to have KRAS wild type, and 50 patients were found to have KRAS mutant type mutation, according to Veccia et al. (2022)
• Key KRAS Inhibitors Companies: Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines, Roche/Genentech, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others
• Key KRAS Inhibitors Therapies: JDQ443, Avutometinib, BI 1701963, GDC-6036, LY353798, RMC-4630, Divarasib, Onvansertib, IMM-1-104, Glecirasib (JAB-21822), BBP-398, MRTX1133, DCC-3116, ELI-002, D-1553, SLATE-KRAS, D3S-001, and others
• KRASG12C is found in about 37% of NSCLC patients in the US. KRASG12D was present in pancreatic cancer and CRC at the highest rates-42% and 30%, respectively
• The KRAS Inhibitors market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage KRAS Inhibitors pipeline products will significantly revolutionize the KRAS Inhibitors market dynamics.

KRAS Inhibitors Overview
One of the most frequent abnormalities in cancer, particularly non-small cell lung cancer (NSCLC), is a mutation in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Designing targeted small molecule therapeutics is difficult due to the KRAS protein's lack of an appropriate small molecule binding site and its strong affinity for the quantity of cellular guanosine triphosphate (GTP).

Get a Free sample for the KRAS Inhibitors Market Report
https://www.delveinsight.com/report-store/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

KRAS Inhibitors Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

KRAS Inhibitors Epidemiology Segmentation:
The KRAS Inhibitors market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of KRAS Inhibitors
• Prevalent Cases of KRAS Inhibitors by severity
• Gender-specific Prevalence of KRAS Inhibitors
• Diagnosed Cases of Episodic and Chronic KRAS Inhibitors

Download the report to understand which factors are driving KRAS Inhibitors epidemiology trends @ KRAS Inhibitors Epidemiology Forecast
https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

KRAS Inhibitors Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the KRAS Inhibitors market or expected to get launched during the study period. The analysis covers KRAS Inhibitors market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the KRAS Inhibitors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

KRAS Inhibitors Therapies and Key Companies
• JDQ443: Novartis
• Avutometinib: Verastem Oncology
• BI 1701963: Boehringer Ingelheim
• GDC-6036: Roche
• LY353798: Eli Lilly
• RMC-4630: Revolution Medicines
• Divarasib: Roche/Genentech
• Onvansertib: Cardiff Oncology
• IMM-1-104: Immuneering Corporation
• Glecirasib (JAB-21822): Jacobio Pharmaceuticals
• BBP-398: BridgeBio Pharma (Navire Pharma)
• MRTX1133: Mirati Therapeutics
• DCC-3116: Deciphera Pharmaceuticals
• ELI-002: Elicio Therapeutics
• D-1553: InventisBio
• SLATE-KRAS: Gritstone Bio
• D3S-001: D3 Bio

Discover more about therapies set to grab major KRAS Inhibitors market share @ KRAS Inhibitors Treatment Market
https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

KRAS Inhibitors Market Strengths
• Combining KRAS-targeted therapies with other treatment modalities, such as immunotherapies or traditional chemotherapy, holds promise for improving treatment outcomes. The potential for combination therapies creates additional market opportunities and enhances the overall market strength of KRAS mutations

KRAS Inhibitors Market Opportunities
• To enhance the effectiveness of KRASG12C inhibitors in NSCLC, it is crucial to integrate them into the first-line standard of care (SOC). Nevertheless, the currently available agents have encountered difficulties due to toxic side effects when combined with anti-PD-(L)1 therapy.

Scope of the KRAS Inhibitors Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key KRAS Inhibitors Companies: Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines, Roche/Genentech, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others
• Key KRAS Inhibitors Therapies: JDQ443, Avutometinib, BI 1701963, GDC-6036, LY353798, RMC-4630, Divarasib, Onvansertib, IMM-1-104, Glecirasib (JAB-21822), BBP-398, MRTX1133, DCC-3116, ELI-002, D-1553, SLATE-KRAS, D3S-001, and others
• KRAS Inhibitors Therapeutic Assessment: KRAS Inhibitors current marketed and KRAS Inhibitors emerging therapies
• KRAS Inhibitors Market Dynamics: KRAS Inhibitors market drivers and KRAS Inhibitors market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• KRAS Inhibitors Unmet Needs, KOL's views, Analyst's views, KRAS Inhibitors Market Access and Reimbursement

To know more about KRAS Inhibitors companies working in the treatment market, visit @ KRAS Inhibitors Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. KRAS Inhibitors Market Report Introduction
2. Executive Summary for KRAS Inhibitors
3. SWOT analysis of KRAS Inhibitors
4. KRAS Inhibitors Patient Share (%) Overview at a Glance
5. KRAS Inhibitors Market Overview at a Glance
6. KRAS Inhibitors Disease Background and Overview
7. KRAS Inhibitors Epidemiology and Patient Population
8. Country-Specific Patient Population of KRAS Inhibitors
9. KRAS Inhibitors Current Treatment and Medical Practices
10. KRAS Inhibitors Unmet Needs
11. KRAS Inhibitors Emerging Therapies
12. KRAS Inhibitors Market Outlook
13. Country-Wise KRAS Inhibitors Market Analysis (2019-2032)
14. KRAS Inhibitors Market Access and Reimbursement of Therapies
15. KRAS Inhibitors Market Drivers
16. KRAS Inhibitors Market Barriers
17. KRAS Inhibitors Appendix
18. KRAS Inhibitors Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports by DelveInsight

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.